CMC in Preclinical Development – is Polymorph Screening Appropriate?

I was fortunate to be invited to participate in a recent MPI Research sponsored event at the WBBA facility in Seattle, Washington. Titled “Chemical Manufacturing Controls: What’s Driving the Entire Drug Development Process?” it addressed those scientific and regulatory aspects of drug characterization needed at the pre-clinical stage of development. The meeting was excellently...

Read More

COO Musings – Transitions from Big Pharmaceutical to Life as a CRO

The Velesco team made a significant transition as each of us worked for many years in big pharma and the skills we needed to succeed in a small business were different in many ways. Prior to co-founding Velesco, I worked in R&D financial operations and was not exposed to the range of disciplines that one is required to master to successfully lead a start up CRO. An early learning for us was...

Read More

Cyclodextrins as Early Stage Toxicology Formulation Solubilizers: These Things are Really Cool.

Cyclodextrins are powerful tools in the early stage formulator’s toolbox, especially with the poorly soluble compounds that we are frequently formulating.  Many of our clients are unfamiliar with these compounds, their limitations, and how they can be used for formulation.  One large advantage is that Cyclodextrins are typically water soluble, and therefore your formulation can be appropriate...

Read More

Introduction to the Velesco Pharma Blog

Velesco recently celebrated its 5th anniversary and we thought the timing quite appropriate to initiate a blog to enhance our interaction with the significant network we have developed in the pharmaceutical R&D community.  Our colleagues come from a diverse yet common background.  All are from the range of big pharma R&D organizations that once excelled in Michigan and the midwest. My...

Read More